Fleming, Gini F., Saha, Poornima, Burstein, Harold J., Parmar, Vani, Torres, Roberto, Stewart, Josephine, Bellet, Meritxell, Perello, Antonia, Dane, Faysal, Moreira, Antonio, Vorobiof, Daniel, Nottage, Michelle, Regan, Meredith M., Price, Karen N., Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Colleoni, Marco, Pagani, Olivia, Francis, Prudence A., Walley, Barbara A., Ribi, Karin, Bernhard, Jurg, Luo, Weixiu, Gomez, Henry L.. American Society of Clinical Oncology; 2017. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy trials.

Ribi, Karin, Luo, Weixiu, Ruhstaller, Thomas, Abdi, Ehtesham, Biganzoli, Laura, Müller, Bettina, Barbeaux, Annelore, Graas, Marie-Pascale, Rabaglio, Manuela, Francis, Prudence A., Foukakis, Theodoros, Pagani, Olivia, Colleoni, Marco, Graiff, Claudio, Vorobiof, Daniel, Maibach, Rudolf, Di Leo, Angelo, Gelber, Richard D., Goldhirsch, Aron, Coates, Alan S., Regan, Meredith M., Bernhard, Jürg, Karlsson, Per, Chirgwin, Jacquie, Aebi, Stefan, Jerusalem, Guy, Neven, Patrick, Di Lauro, Vincenzo, Gomez, Henry L.. Nature Publishing Group; 2019. Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.

Ribi, Karin, Luo, Weixiu, Walley, Barbara A., Burstein, Harold J., Chirgwin, Jacquie, Ansari, Rafat H., Salim, Muhammed, van der Westhuizen, Andre, Abdi, Ehtesham, Francis, Prudence A., Chia, Stephen, Harvey, Vernon J., Giobbie-Hurder, Anita, Fleming, Gini F., Pagani, Olivia, Di Leo, Angelo, Colleoni, Marco, Gelber, Richard D., Goldhirsch, Aron, Coates, Alan S.. Springer; 2020. Treatment-induced symptoms, depression and age as predictors of sexual problem in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.

Regan, Meredith M., Pagani, Olivia, Villani, Laura, Pizzolitto, Stefano, Öhlschlegel, Christian, Sessa, Fausto, Peg Cámara, Vicente, Rodríguez Peralto, José Luis, MacGrogan, Gaëtan, Colleoni, Marco, Goldhirsch, Aron, Price, Karen N., Francis, Prudence A., Coates, Alan S., Gelber, Richard D., Viale, Giuseppe, Fleming, Gini F., Walley, Barbara A., Kammler, Roswitha, Dell'Orto, Patrizia, Russo, Leila, Szőke, János, Doimi, Franco. Springer; 2015. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.

Goldhirsch, A., Winer, E. P., Bonnefoi, Hervé, Bretel-Morales, Denisse, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Colleoni, Marco, Costa, Alberto, Curigliano, Giuseppe, Davidson, Nancy E., Leo, Angelo Di, Coates, A. S., Ejlertsen, Bent, Forbes, John F., Gelber, Richard D., Gnat, Michael, Goldhirsch, Aron, Goodwin, Pamela, Goss, Paul E., Harris, Jay R., Hayes, Daniel F., Hudis, Clifford A., Gelber, R. D., Ingle, James N., Jassem, Jacek, Jiang, Zefei, Karlsson, Per, Loibl, Sibylle, Morrow, Monica, Namer, Moise, Osborne, C. Kent, Partridge , Ann H., Penault-Llorca, Fréderiqué, Piccart-Gebhart, M., Perou, Charles M., Piccart-Gebhart, Martine, Pritchard, Kathleen I., Rutgers, Emiel J. T., Sedlmayer, Felix, Semiglazov, Vladimir, Shao, Zhi-Ming, Smith, Ian, Thürlimann, Beat, Toi, Masakazu, , Tutt, Andrew, Untch, Michael, Viale, Giuseppe, Watanabe, Toru, Wilcken, Nicholas, Winer, Eric P., Wood, William C., Senn, H. - J., Albain, Kathy S., André, Fabrice, Bergh, Jonas. Oxford University Press; 2013. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013.

Moore, Halle C. F., Unger, Joseph M., Partridge, Anne H., Dakhil, Shaker R., Garcia, Agustin A., Gralow, Julie, Lombard, Janine M, Forbe, John F., Martino, Silvana, Barlow, William E., Fabian, Carol J., Minasian, Lori, Phillips, Kelly-Anne, Meyskens, Frank L. Jr, Gelber, Richard D., Hortobagyi, Gabriel N, Albain, Kathy S., Boyle, Frances, Hitre, Erika, Porter, David, Francis, Prudence A., Goldstein, Lori J., Gomez, Henry L., Vallejos, Carlos S.. Lippincott Williams & Wilkins; 2015. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

Crivellari, Diana, Sun, Zhuoxin, Gelber, Richard D., Colleoni, Marco, Lang, Istvan, Del Mastro, Lucia, Gladieff, Laurence, Rabaglio, Manuela, Smith, Ian E., Chirgwin, Jacquie H., Goldhirsch, Aron, Coates, Alan S., Price, Karen N., Thurlimann, Beat, Mouridsen, Henning, Mauriac, Louis, Forbes, John F., Paridaens, Robert J., Castiglione-Gertsch, Monica. American Society of Clinical Oncology; 2008. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.

Zeidan, Youssef H., Habib, Joyce G., Ameye, Lieveke, Paesmans, Marianne, de Azambuja, Evandro, Gelber, Richard D., Campbell, Ian, Nordenskjöld, Bo, Gutiérez, Jorge, Anderson, Michael, Lluch, Ana, Gnant, Michael, Goldhirsch, Aron, Di Leo, Angelo, Joseph, David J., Crown, John, Piccart-Gebhart, Martine, Francis, Prudence A.. Elsevier; 2018. Postmastectomy radiation therapy in women with T1-T2 tumors and 1 to 3 positive lymph nodes: analysis of the Breast International Group 02-98 Trial.

Ewertz, Marianne, Gray, Kathryn P., Gelber, Richard D., Colleoni, Marco, Láng, István, Smith, Ian E., Coates, Alan S., Goldhirsch, Aron, Mouridsen, Henning T., Regan, Meredith M., Ejlertsen, Bent, Price, Karen N., Thürlimann, Beat, Bonnefoi, Hervé, Forbes, John F., Paridaens, Robert J., Rabaglio, Manuela. American Society of Clinical Oncology; 2012. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 trial.

Rasmussen, Birgitte B., Regan, Meredith M., Braye, Stephen, Altermatt, Hans J., Gelber, Richard D., Castiglione-Gertsch, Monica, Goldhirsch, Aron, Gusterson, Barry A., Thürlimann, Beat, Coates, Alan S., Viale, Giuseppe, Lykkesfeldt, Anne E., Dell'Orto, Patrizia, Del Curto, Barbara, Henriksen, Katrine L., Mastropasqua, Mauro G., Price, Karen N., Méry, Eliane E., Lacroix-Triki, Magali. Elsevier; 2008. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

Colleoni, Marco, Giobbie-Hurder, Anita, Chirgwin, Jacquie, Pienkowski, Tadeusz, Wardley, Andrew, Price, Karen N., Gelber, Richard D., Coates, Alan S., Goldhirsch, Aron, Regan, Meredith M., Thürlimann, Beat, Mouridsen, Henning, Mauriac, Louis, Forbes, John F., Paridaens, Robert, Láng, István, Smith, Ian. American Society of Clinical Oncology; 2011. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 Study.

Moore, Halle C. F., Unger, Joseph M., Partridge, Ann H., Dakhil, Shaker R., Garcia, Agustin A., Gralow, Julie, Lombard, Janine M., Forbes, John F., Martino, Silvana, Barlow, William E., Fabian, Carol J., Minasian, Lori, Phillips, Kelly-Anne, Meyskens, Frank L., Gelber, Richard D., Hortobagyi, Gabriel N., Albain, Kathy S., , Boyle, Frances, Hitre, Erika, Porter, David, Francis, Prudence A., Goldstein, Lori J., Gomez, Henry L., Vallejos, Carlos S.. Massachusetts Medical Society; 2015. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

Colleoni, Marco, Gray, Kathryb P., Tondini, Carlo, Kralidis, Elena, Eniu, Alexandru, Cagossi, Katia, Rauch, Daniel, Chirgwin, Jacquie, Gelber, Richard D., Regan, Meredith M., Coates, Alan S., Price, Karen N., Gelber, Shari, , , Láng, István, Thürlimann, Beat, Gianni, Lorenzo, Abdi, Ehtesham A., Gomez, Henry L., Linderholm, Barbro K., Puglisi, Fabio. American Society of Clinical Oncology; 2016. Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00.

Viale, Giuseppe, Regan, Meredith M., Braye, Stephen, Grigolato, Piergiovanni, Rusca, Tiziana, Gelber, Richard D., Castiglione-Gertsch, Monica, Price, Karen N., Goldhirsch, Aron, Gusterson, Barry A., Coates, Alan S., Maiorano, Eugenio, Mastropasqua, Mauro G., Golouh, Rastko, Perin, Tiziana, Brown, Robert W., Kovacs, Aniko, Pillay, Komala, Ohlschlegel, Christian. American Society of Clinical Oncology; 2008. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors - International Breast Cancer Study Group.

Ribi, Karin, Luo, Weixiu, Chia, Stephen, Harvey, Vernon J., Giobbie-Hurder, Anita, Fleming, Gini F., Pagani, Olivia, Di Leo, Angelo, Colleoni, Marco, Gelber, Richard D., Goldhirsch, Aron, Coates, Alan S., Walley, Barbara A., Regan, Meredith M., Bernhard, Jürg, Burstein, Harold J., Chirgwin, Jacquie, Ansari, Rafat H., Salim, Muhammed, van der Westhuizen, Andre, Abdi, Ehtesham, Francis, Prudence A.. Springer; 2020. Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.

Thürlimann, Beat, Price, Karen N., Goldhirsch, Aron, Gelber, Richard D., Holmberg, Stig B., Crivellari, Diana, Colleoni, Marco, Collins, John, Forbes, John F., Castiglione-Gertsch, Monica, Coates, Alan S.. Springer; 2009. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-Year update of International Breast Cancer Study Group Trial 11-93.

Bernhard, Jürg, Luo, Weixiu, Pavesi, Lorenzo, Parmar, Vani, Regan, Meredith M., Pagani, Olivia, Fleming, Gini F., Francis, Prudence A., Price, Karen N., Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Ribi, Karin, Walley, Barbara A., Colleoni, Marco, Burstein, Harold J., Tondini, Carlo, Pinotti, Graziella, Spazzapan, Simon, Ruhstaller, Thomas, Puglisi, Fabio. Elsevier; 2015. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

Ribi, Karin, Luo, Weixiu, Parmar, Vani, Tondini, Carlo, Kerbrat, Pierre, Perelló, Antonia, Neven, Patrick, Torres, Roberto, Lombardi, Davide, Puglisi, Fabio, Karlsson, Per, Ruhstaller, Thomas, Bernhard, Jürg, Colleoni, Marco, Coates, Alan S., Goldhirsch, Aron, Price, Karen N., Gelber, Richard D., Regan, Merideth M., Fleming, Gini F., Francis, Prudence A., Burstein, Harold J., Ciruelos, Eva, Bellet, Meritxell, Pavesi, Lorenzo, Lluch, Ana, Visini, Marilena. American Society of Clinical Oncology; 2016. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial.

Regan, Meredith M., Neven, Patrick, Rabaglio, Manuela, Price, Karen N., Gelber, Richard D., Coates, Alan S., Thürlimann, Beat, Giobbie-Hurder, Anita, Goldhirsch, Aron, Ejlertsen, Bent, Mauriac, Louis, Forbes, John F., Smith, Ian, Láng, István, Wardley, Andrew. Elsevier; 2011. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up.

Colleoni, Marco, Sun, Zhuoxin, Goldhirsch, Aron, Price, Karen N., Karlsson, Per, Forbes, John F., Thürlimann, Beat, Gianni, Lorenzo, Castiglione, Monica, Gelber, Richard D., Coates, Alan S.. American Society of Clinical Oncology; 2016. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V.

Chirgwin, Jacquie H., Giobbie-Hurder, Anita, Forbes, John F., Neven, Patrick, Láng, István, Colleoni, Marco, Thürlimann, Beat, Coates, Alan S., Price, Karen N., Ejlertsen, Bent, Debled, Marc, Gelber, Richard D., Goldhirsch, Aron, Smith, Ian, Rabaglio, Manuela. American Society of Clinical Oncology; 2016. Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence.

Johansson, Harriet, Gray, Kathryn P., Colleoni, Marco, Rabaglio, Manuela, Price, Karen N., Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Kammler, Roswitha, Bonanni, Bernardo, Walley, Barbara A., TEXT principal investigators,, Pagani, Olivia, Chirgwin, Jaqueline, Francis, Prudence, Regan, Meredith M., Viale, Giuseppe, Aristarco, Valentina, Macis, Debora, Puccio, Antonella, Roux, Susanne, Maibach, Rudolf. BioMed Central; 2016. Impact of CYO19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.

Regan, Meredith M., Francis, Prudence A., Pinotti, Graziella, Price, Karen N., Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Pagani, Olivia, Fleming, Gini F., Walley, Barbara A., Viale, Giuseppe, Colleoni, Marco, Láng, István, Gómez, Henry L., Tondini, Carlo. American Society of Clinical Oncology; 2016. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer: TEXT and SOFT Trials.

Francis, Prudence A., Regan, Meredith M., Martino, Silvana, Davidson, Nancy E., Geyer, Charles E., Walley, Barbara A., Coleman, Robert, Kerbrat, Pierre, Buchholz, Stefan, Ingle, James N., Winer, Eric P., Rabaglio-Poretti, Manuela, Fleming, Gini F., Maibach, Rudolf, Ruepp, Barbara, Giobbie-Hurder, Anita, Price, Karen N., Colleoni, Marco, Viale, Giuseppe, Coates, Alan S., Goldhirsch, Aron, Gelber, Richard D., Lang, István Láng, Ciruelos, Eva, Bellet, Meritxell, Bonnefoi, Hervé R., Climent, Miguel A., Da Prada, Gian Antonio, Burstein, Harold J.. Massachusetts Medical Society; 2015. Adjuvant ovarian suppression in premenopausal breast cancer.

Pagani, Olivia, Gelber, Shari, Thürlimann, Beat, Fey, Martin F., Murray, Elizabeth, Forbes, John F., Coates, Alan S., Goldhirsch, Aron, Simoncini, Edda, Castiglione-Gertsch, Monica, Price, Karen N., Gelber, Richard D., Holmberg, Stig B., Crivellari, Diana, Collins, John, Lindtner, Jurij. Springer; 2009. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.

Regan, Meredith M., Pagani, Olivia, Colleoni, Marco, Gelber, Richard D., Francis, Prudence A., International Breast Cancer Study Group (IBCSG),, SOFT Investigators,, TEXT Investigators,, Fleming, Gini F., Walley, Barbara A., Price, Karen N., Rabaglio, Manuela, Maibach, Rudolf, Ruepp, Barbara, Coates, Alan S., Goldhirsch, Aron. Elsevier; 2013. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.

Francis, Prudence A., Pagani, Olivia, Bennefoi, Herve R., Bellet, Meritxell, Martino, Silvana, Geyer, Jr., Charles E., Goetz, Matthew P., Stearns, Vered, Pinotti, Graziella, Puglisi, Fabio, Spazzapan, Simon, Climent, Miguel A., Fleming, Gini F., Pavesi, Lorenzo, Ruhstaller, Thomas, Davidson, Nancy E., Coleman, Robert, Debled, Marc, Buchholz, Stefan, Ingle, James N., Winer, Eric P., Maibach, Rudolf, Rabaglio-Poretti, Manuela, Walley, Barbara A., Ruepp, Barbara, Di Leo, Angelo, Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Regan, Meredith M., Colleoni, Marco, Lang, Istvan, Gomez, Henry L., Tondini, Carlo, Ciruelos, Eva, Burstein, Harold J.. Massachusetts Medical Society; 2018. Tailoring adjuvant endocrine therapy for premenopausal breast cancer.